Two treatments, two different jobs

The question most patients arrive with — which injection is right for me? — cannot be answered by comparing the two treatments side by side. It can only be answered by looking at what the MRI shows.

ChondroFiller and PRP are designed for different problems. ChondroFiller is a structural scaffold: it is used when imaging confirms a focal, localised cartilage defect — a defined area of damage in an otherwise mechanically sound joint. PRP works differently, acting on the joint's biological environment to reduce inflammation and modify the conditions driving pain and degeneration; it tends to be considered where the picture is one of more diffuse osteoarthritic change rather than a discrete structural lesion.

That diagnostic distinction — focal defect versus generalised degeneration — is the first clinical decision point. Neither treatment is a candidate where arthritis has progressed to end-stage, bone-on-bone disease. And because no direct head-to-head trials exist, no evidence-based ranking between them is possible. Clinicians choose on the basis of what the joint actually needs, not personal preference.

ChondroFiller: an injectable scaffold for focal defects

ChondroFiller is made from Type I collagen — the same structural protein found in healthy cartilage — acid-extracted and formulated as a liquid that self-polymerises on contact with the neutral pH environment inside the joint. Within roughly three to five minutes of injection, it solidifies into a dimensionally stable, porous three-dimensional lattice that occupies the structural gap.

The scaffold contains no donor cells and requires no laboratory preparation in advance. Its mechanism is indirect: it creates a framework into which the patient's own chondrocytes — the cells responsible for producing and maintaining cartilage — can migrate and begin building new tissue. The material establishes the conditions for repair rather than substituting for cartilage itself.

The treatment is indicated for focal cartilage defects — a localised area of missing or damaged cartilage, typically up to 3 cm², in a joint whose mechanical alignment is otherwise intact. That is different from the more diffuse, patchy wear that characterises osteoarthritis. A 2025 prospective study (PMC12498443) provided objective evidence of effect: ChondroFiller-treated joints showed significantly better cartilage quality at follow-up than untreated controls on both Outerbridge and ICRS grading scales (P=0.006 and P=0.002 respectively), with fibrous tissue formation observed only in cases where the defect had been overfilled.

Delivery is via ultrasound-guided outpatient injection — no surgical incision, theatre admission, or general anaesthetic is involved. ChondroFiller carries CE marking in Europe but is not currently FDA-approved in the United States. In the UK, it is available only through self-funded private care.

PRP: a biological modifier for inflammation and degeneration

Concentrating a patient's own platelets several times above their normal circulating level, PRP releases growth factors and cytokines — including PDGF, TGF-β, and VEGF — into the joint space on injection. The effect is biological rather than structural: these signalling proteins reduce inflammation and support cellular activity, and in some patients may slow cartilage breakdown in joints affected by osteoarthritis or diffuse degenerative wear. A 2022 narrative review analysing 13 clinical trials (PMC9465610) found broadly positive effects on inflammation, angiogenesis, and cellular proliferation — though the same review noted that the absence of standardised preparation protocols limits how reliably those findings translate across different clinical settings.

That variability matters in practice. Centrifuge speed, spin duration, and whether leucocytes are retained or removed all affect the final product, meaning "PRP" covers a spectrum of preparations rather than a single standardised treatment. Meta-analyses suggest leukocyte-poor formulations are associated with better functional outcomes than leukocyte-rich versions, but preparation protocols are not always disclosed to patients.

Where PRP shows its clearest benefit is in pain and function scores. Published meta-analyses report WOMAC and VAS improvements that outperform hyaluronic acid at six, twelve, and up to sixty months of follow-up. What PRP does not reliably produce is structural cartilage regrowth: MRI studies consistently show minimal hyaline cartilage regeneration — typically in the region of 0–5% — and any tissue healing that does occur tends to result in fibrocartilage rather than true articular cartilage. It is, in that sense, a biological modifier rather than a structural repair.

PRP is widely available in private UK settings and is used globally; autologous blood products processed and re-injected in the same clinical encounter do not face the same regulatory approval requirements as scaffold-based devices.

What the clinical evidence shows

Published series for ChondroFiller report IKDC score improvements of approximately 30 points in knee cohorts, with MOCART MRI regeneration scores — a standard measure of cartilage fill quality on imaging — in the range of 70 to 87. Around four in five patients in published cohorts described their outcome as good or very good and indicated they would undergo the treatment again. That picture is encouraging, but the evidence base is still maturing: robust randomised controlled trial data specifically for knee cartilage lesions remains limited compared with longer-established interventions, and the field will require further large-scale studies to quantify effect sizes with greater confidence.

For PRP, the evidence cuts in two directions. Meta-analyses of RCTs confirm meaningful advantages over hyaluronic acid on pain and function scores at six, twelve, and up to sixty months — a sustained benefit relative to an established comparator. Set against that is the 2021 JAMA RCT by Bennell et al. — one of the most cited trials in this area, with over 500 citations — which found PRP injections did not significantly improve knee pain or reduce medial tibial cartilage volume loss compared with placebo at twelve months. Both findings belong in an honest account: the meta-analysis advantage over hyaluronic acid is real, and so is the null result against placebo.

No completed trial has placed ChondroFiller and PRP head to head, and the populations underpinning each body of evidence differ — focal cartilage lesions in one case, osteoarthritis-predominant cohorts in the other — meaning outcome rankings between the two cannot be drawn from the current literature.

Which patients are suited to each treatment

Rather than weighing up the two treatments in the abstract, the practical clinical question is simpler: what does the MRI actually show? That single finding — not a patient's description of pain, nor their age or activity level alone — is the primary gateway to both pathways.

An MRI revealing a focal cartilage defect — a discrete, localised area of damage, typically up to around 3 cm² — within an otherwise mechanically sound joint points toward a structural repair approach. These lesions often arise from a specific injury or impact rather than generalised wear, and they are the category ChondroFiller is designed to address.

Where imaging shows diffuse osteoarthritic change — widespread cartilage thinning across the joint surface rather than a contained defect — the picture is one of degeneration rather than a structural void. PRP's role as a biological modifier is more applicable here, aiming to reduce inflammation and support joint function rather than fill a defined gap.

Neither treatment is appropriate where imaging confirms advanced bone-on-bone wear; at that stage, injection therapies of either type sit outside what the evidence supports as effective.

Combination approaches — for example, sequencing both treatments in suitable patients — are used in certain clinical contexts, but that decision requires individual assessment and falls outside a straightforward either/or comparison.

For most patients, the practical starting point is an ultrasound or MRI assessment with a specialist. The scan defines the problem; what the problem looks like on imaging shapes the conversation about which pathway makes sense.

Access, cost, and what the appointment involves

For most patients in the UK, the access question arrives before the clinical one: where can this be done, and through which route?

ChondroFiller carries CE marking in Europe and has been in clinical use there for nearly two decades, but it is not currently FDA-approved in the United States. In the UK it sits outside NHS funding and is available only through self-funded private care. PRP faces fewer access constraints — it is available through private sports-medicine and orthopaedic clinics, and some NHS-adjacent pathways include it depending on the referring service.

Both treatments are delivered as outpatient injection appointments. ChondroFiller is placed under image guidance directly into the cartilage defect site; PRP involves a blood draw, a brief centrifugation step to concentrate the platelets, and an intra-articular injection — typically completed within a single appointment.

Costs vary by provider and by what the package includes. Before committing, it is worth asking whether imaging, follow-up appointments, and any repeat injections are included in the quoted fee, or priced separately — the answer affects the real cost of a course of treatment significantly.

The appropriate starting point is a suitability assessment with a specialist, ideally supported by recent MRI, rather than booking either treatment directly. That assessment confirms whether a focal lesion or diffuse degeneration is present, and shapes which pathway — if either — is clinically appropriate for that individual.